Skip to main content

Featured

The Subway That Took a Generation: Why the Eglinton Crosstown’s Delays Were Even Worse Than You Think

  Toronto has a long history of transit projects that drag on, but the Eglinton Crosstown LRT has become the city’s defining example of how complicated, political, and painfully slow building transit can be. Most people think of the project as something that started in the early 2010s and simply ran over schedule. The truth is far messier—and stretches back decades. A Project With Roots in the 1990s Long before shovels hit the ground in 2011, the idea of rapid transit along Eglinton was already alive. In the mid‑1990s, the TTC began digging tunnels for what was then called the Eglinton West Subway . Construction actually started—tunnels were being carved out under the street—until the project was abruptly cancelled in 1995. The partially built tunnels were filled in, and the corridor sat untouched for years. That early false start meant that by the time the Crosstown was revived as part of the Transit City plan in 2007, planners weren’t starting fresh. They were restarting a dr...
Post a Comment
Read more

article

Labels

What is JN.1, the new COVID-19 variant?

 


JN.1 is a new COVID-19 variant that is spreading quickly in the United States and Canada. It is a subvariant of the Omicron family, which was responsible for the 2022 surge that overwhelmed health care systems across the globe. According to the Centers for Disease Control and Prevention (CDC),

JN.1 is currently the fastest growing variant, accounting for more than one fifth of all COVID infections in the U.S. By the end of the month, it’s also projected to account for more than 40 per cent of cases in Canada. Earlier this week, the World Health Organization (WHO) classified the JN.1 coronavirus strain as a “variant of interest” due to its rapid spread.

The risk to the public is low from this specific strain, but it could increase the burden of respiratory infections in many countries. JN.1 is causing a rise in infections and seems to be exerting its dominance in multiple settings around the world. Dr. Zain Chagla, infectious disease physician and head of infectious disease services at St. Joseph’s Health Care in Hamilton, Ont. recently told Yahoo Canada that JN.1 is considered the “offspring” of a strain we have dealt with before: BA.2.86, also known as “Pirola,” which has been spreading since the summer. Both variants are descendents of Omicron and, according to the CDC, are nearly identical.

The only difference between JN.1 and BA.2.86 is a single spike protein, which helps the virus better invade human cells. This small mutation may be enough to make the strain predisposed to better receptor binding and better antibody evasiveness. This can lead to the strain’s ability to “cause an impact in terms of spread or the ability to infect populations.”

Symptoms of JN.1

According to the CDC, symptoms of a JN.1 COVID-19 infection may include:

  • Cough
  • Sore throat
  • Headache
  • Muscle aches
  • Fever
  • Change in or loss of taste or smell
  • Congestion and runny nose

JN.1 is a highly mutated COVID-19 variant that is now the fastest growing variant in the U.S. and Canada. It is closely related to a strain we’ve seen before, BA.2.86, which has been spreading in the U.S. since the summer. JN.1 has one more mutation compared to its parent strain BA.2.86, which has more than 30 mutations that set it apart from the omicron XBB.1.5 variant. JN.1’s growth comes as COVID hospitalizations rise quickly, influenza continues to spread and RSV activity is still high in many places, according to a Dec. 14 update from the CDC. The agency warned that at the end of the month, emergency rooms and hospitals could become strained, similarly to last year, especially in the South.


Labels:

Comments

Post a Comment